ХИМИОТЕРАПИЯ МЕТАСТАТИЧЕСКИХ НЕЙРОЭНДОКРИННЫХ ОПУХОЛЕЙ АРАНОЗОЙ В МОНОРЕЖИМЕ И В КОМБИНАЦИИ С КАПЕЦИТАБИНОМ И ТЕМОЗОЛОМИДОМ

The article presents the results of a clinical study, the aim of which was to evaluate the efficacy and safety of chemotherapy regimens based on nitrosoureas derivative aranose used in 1-5 line therapy for metastatic neuroendocrine tumors (mNET) of different localization. Patients (n = 49) included in the study received one of three regimens: monotherapy with aranose (480-690 mg/m2 intravenously on 1 st -3 rd days every 3 weeks), aranose in combination with capecitabine (aranose 500 -760 mg / m2 intravenously 1 st -2 nd days; capecitabine 2g / m2 / day 1 st -14 th days every 3 weeks) and aranose in combination with temozolomide (aranose, 450 mg / m2 intravenously 1 st -2 nd days; temozolomide 100 mg / m2 / day 3 rd -6 th days every 3 weeks). Monotherapy with aranose received 20 patients, aranose/ capecitabine combination - 22 patients, and aranose / temozolomide combination - 7 patients. A total of 337 courses of chemotherapy were conducted. According to the assessment of the effectiveness of aranose, aranose/capecitabine, aranose/temozolomide regimens objective response rate was 40%; 22.7%; 28.6%, respectively, and the control the tumor growth was 75%; 77.3%; 57.2% respectively. All these regimens were well tolerated. The most frequent adverse event was 1-2 grade of hematologic toxicity. Thus, aranose in monotherapy and in combination with other cytostatics showed anti-tumor activity and characterized with satisfactory tolerability.